If you have von Willebrand disease, we would like your views on a new synthetic treatment which could finally get approved this month.
The first recombinant treatment for VWD, Vonicog Alfa, was rejected by NHS England earlier this year, but will be reviewed again at the end of this month.
Without this recombinant option, people with VWD who need factor cover during surgery or for bleeding complications still have to rely on plasma-based treatment.
The Haemophilia Society has already submitted evidence gathered from a survey carried out in 2019, but would like to give additional patient feedback in the hope that the treatment is commissioned for NHS use this time.
Vonicog Alfa, also known as Veyvondi, works in the same way as von Willebrand factor made by the body itself, by replacing the protein needed to stop bleeding that is missing or not working.
If having a recombinant option for VWD is important to you or a family member, please comment below or email us at email@example.com before 20 July.